Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Is Howard done with biopsies “forever”?

One of the questions that has been nagging at Howard Wolinsky for a while now is whether he really needs to have another biopsy … ever! … READ MORE …

Should SBRT be THE preferred treatment for intermediate-risk prostate cancer?

Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …

Does TRT really delay biochemical recurrence after radical prostatectomy (in selected patients)?

Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Wide uptake of active surveillance across VA medical system

A research letter in the Journal of the American Medical Association reports a major uptake in the application of active surveillance as a first-line form of management of prostate cancer across the Veterans Affairs health system here in the US since 2005. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

Tookad-Soluble + VTP effective and safe in treatment of low-risk prostate cancer

Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …

PRIAS reports data from a 5,000+ patient active surveillance study

Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …

Just “delaying” surgery does increase risk … but it’s not active surveillance

A key question for men diagnosed with low-risk prostate cancer is always going to be whether, and for how long, they can defer treatment without increasing the risk that delayed treatment will be less effective (or riskier) in some ways. … READ MORE …

One patient’s journey to active surveillance

A personal story on the MedPage Today web site this week tells a tale of how one 63-year-old professional journalist trod his own journey to management of his low-risk prostate cancer on active surveillance back in 2010. It may be instructive for many other patients newly diagnosed with low- and very low-risk prostate cancer.

ICER/Families USA “Proven Best Choices” for treatment of low-risk prostate cancer

According to a report from Kaiser Health News, the consumer organization Families USA is collaborating with the Institute for Clinical and Economic Review (ICER) to provide a series of “Proven Best Choices” guides for patients about screening and treatments for selected disorders. … READ MORE …

What it really costs to manage/treat low-risk prostate cancer

In a new article in the journal Cancer, a research group associated primarily with the University of California, Los Angeles, have provided detailed information on the costs of first-line management of low-risk prostate cancer. … READ MORE …

Slow but increasing uptake of observation in initial management of low-risk patients

A new article by Maurice et al. in the Canadian Urological Association Journal provides detailed information about the use of initial observation as a management strategy for low-risk prostate cancer between 2004 and 2011. … READ MORE …

MUSIC to the ears of advocates for active surveillance

A new paper from the coordinators of the Michigan Urological Surgery Improvement Collaborative (MUSIC) suggests that as many as 50 percent of newly diagnosed patients with low-risk forms of prostate cancer in Michigan are now receiving initial management on active surveillance (AS). … READ MORE …